NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Socinski, M
  • Creelan, B
  • Horn, L
  • Reck, M
  • Paz-Ares, L
  • Steins, M
  • Felip, E
  • van den Heuvel, M
  • Ciuleanu, TE
  • Badin, F
  • Ready, N
  • Hiltermann, TJN
  • Nair, S
  • Juergens, Rosalyn
  • Peters, S
  • Minenza, E
  • Geese, WJ
  • Bhagavatheeswaran, P
  • Chen, A
  • Carbone, DP

publication date

  • October 2016